EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial

Carlos Brites iD, Iris Montaño-Castellon, María B Arriaga iD, Cleyde Marconi, Rafaela Mayoral, Estela Luz, Camila A Figueredo, Bianca S D Fiuza, Eduardo M Netto

Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e910-e920

DOI: 10.1093/cid/ciag163 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.03.2026. Verfasst von Carlos Brites und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Human T-lymphotropic virus 1, Viral Load, HTLV-I Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação Bahiana de Infectologia, Brazilian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No specific therapy is approved for human T-cell lymphotropic virus type 1 (HTLV-1) infection. We tested the effect of dolutegravir (DTG) on clinical outcomes and on HTLV-1 proviral load (PVL) in adults with HTLV-1 infection.

Methods

We conducted an open-label, randomized controlled phase 2 trial in Salvador, Brazil. Symptomatic adults with HTLV-1 infection were randomized 1:1 to DTG 50 mg once daily or vitamin C (VTC) 500 mg once daily for 48 weeks. We evaluated changes in gait performance (timed 10-meter walk test [T10MWT]). Key secondary endpoints included change in PVL and prespecified neurofunctional and urinary outcomes. Primary analyses emphasized intragroup and between-group comparisons; exploratory per-protocol analyses were performed for neurofunctional measures. Asymptomatic participants were included for PVL and immunological evaluations.

Results

Eighty-three participants (53 symptomatic) were randomized (DTG, n = 43; VTC, n = 40). At week 48, there was no between-group difference in T10MWT. However, DTG use significantly reduced PVL over 48 weeks compared with VTC (P < .001). Exploratory per-protocol analyses found significant improvements associated with DTG use in lower limb spasticity (P < .001), sensory function (light touch, P = .035; pinprick, P = .001), and median nocturia frequency (P = .012). Network analysis of cytokine expression showed a change in the DTG group from baseline to week 48, with loss of negative correlations and a more balanced pattern. DTG was well tolerated, with no unexpected safety signals.

Conclusions

In this pilot randomized trial, DTG use was associated with significantly reduced PVL and improvement in neurofunctional and immunological characteristics of participants in exploratory analyses. These findings provide evidence supporting the use of integrase inhibitors for HTLV-1 infection. Clinical Trials Registration. Brazilian Clinical Trial Register (ReBEC), code RBR-5x7ccxp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHuman T-lymphotropic virus 1Viral LoadHTLV-I InfectionsProvirusesHumansDolutegravirFemaleMaleOxazinesPiperazinesAdultPyridonesMiddle AgedBrazilTreatment OutcomeAged

Stichwörter der Autor:innen

HTLV-1dolutegravirimmune modulationneurofunctional outcomesproviral load

Substanzen

Heterocyclic Compounds, 3-RingDolutegravirOxazinesPiperazinesPyridones

Autor:innen und Institutionen

  • Department of Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil.
  • Fundação Bahiana de Infectologia, Salvador, Brazil.
  • Instituto de Ciências da Saude, Federal University of Bahia, Salvador, Brazil.

ORCID-Profile: Carlos Brites, María B Arriaga

Förderung

  • Fundação Bahiana de Infectologia
  • Brazilian Ministry of Health

Zitieren

APA

Brites, C., Montaño-Castellon, I., Arriaga, M. B., Marconi, C., Mayoral, R., Luz, E., Figueredo, C. A., Fiuza, B. S. D., & Netto, E. M. (2026). Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. Clinical Infectious Diseases, 82(5), e910-e920. https://doi.org/10.1093/cid/ciag163

Vancouver

Brites C, Montaño-Castellon I, Arriaga MB, Marconi C, Mayoral R, Luz E, et al. Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. Clinical Infectious Diseases. 2026;82(5):e910-e920. doi:10.1093/cid/ciag163

BibTeX
@article{Brites2026,
  author = {Brites, Carlos and Montaño-Castellon, Iris and Arriaga, María B and Marconi, Cleyde and Mayoral, Rafaela and Luz, Estela and Figueredo, Camila A and Fiuza, Bianca S D and Netto, Eduardo M},
  title = {Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {5},
  pages = {e910--e920},
  doi = {10.1093/cid/ciag163}
}
Kostenlos starten →